

The company

Reassessment of reimbursement status of medicinal products for cardiovascular disease in ATC groups C02, C03, C07, C08 and C09

16 January 2009

Case no.:
5315-9

The Danish Medicines Agency has reassessed the reimbursement status of medicinal products for cardiovascular disease in ATC groups C02 (antihypertensives), C03 (diuretics), C07 (beta blocking agents), C08 (calcium channel blockers) and C09 (ACE inhibitors, angiotensin-II antagonists and renin inhibitors). As of 1 December 2008 or earlier, your company has notified a price of a one or more of these medicinal products to Medicinpriser.dk.

Some medicinal products in these ATC groups change reimbursement status on **13 July 2009**.

We enclose

- **Decisions**
for medicinal products in the ATC groups relevant to your company.

For the decisions, we have drawn up to or three appendices respectively:

- **Appendix I**
Appendix I is the overall note on consultation containing the Danish Medicines Agency's comments to the most significant points of view raised in the consultation responses received in the process. Appendix I is the same for all decisions (C02, C03, C07, C08 and C09), and it is enclosed in one copy.
- **Appendix II**
We have drawn up an Appendix II for each decision (Appendix II/C02, Appendix II/C03, Appendix II/C07, Appendix II/C08 and Appendix II/C09). This appendix contains an updated price and consumption list of *individual substances* in the ATC group in question.

- **Appendix III**

We have drawn up an Appendix III for each decision with the exception of ATC group C02 (Appendix III/C03, Appendix III/C07, Appendix III/C08 and Appendix III/C09). This appendix contains an updated price and consumption list of *combination products* in the ATC group in question.

Those of your medicinal products, which are comprised by the enclosed decisions, are listed below, specifying the reimbursement status of your company's medicinal products as from **13 July 2009**.

.....
.....
....

The enclosed decisions concern all strengths and pack sizes of the medicinal product(s) in question.

Yours sincerely



Elisabeth Thomsen